Prime Medicine (NYSE:PRME – Get Rating) was upgraded by StockNews.com to a “sell” rating in a research note issued on Tuesday.
Prime Medicine Price Performance
Shares of NYSE:PRME opened at $14.27 on Tuesday. Prime Medicine has a 12-month low of $11.07 and a 12-month high of $21.73.
See Also
- Get a free copy of the StockNews.com research report on Prime Medicine (PRME)
- monday.com Surges on Price and Volume after Blowout Results
- Can Ryanair Stock Fly Above Resistance Levels, What Earnings Show
- All Aboard! The Sell-Side Has Railroads In Reversal
- Is There Value Left in Lyft Stock?
- Everything About ZIM Integrated Screams Undervaluation
Receive News & Ratings for Prime Medicine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prime Medicine and related companies with MarketBeat.com's FREE daily email newsletter.
